In addition, LRG1 has been identified as a useful biomarker to distinguish between patients with active or inactive systemic juvenile idiopathic arthritis and in patients with rheumatoid arthritis during Tocilizumab treatment 8,59. This evidence concerns the gene LRG1 and juvenile idiopathic arthritis.